Voglio sapere a riguardo di…

khammond on DSKJM1Z7X2PROD with NOTICES

36566

Federal Register / Vol. 86, No. 130 / Monday, July 12, 2021 / Notices
11, 2015, HHS Ref. No. E05020150
US01;
II. International Patent Application No. PCT/US2016/022072 filed Mar. 11, 2015, HHS Reference No. E0502015
0PCT03; expired III. Australian National Stage Patent Application No. 2016228751, filed Mar.
11, 2016, HHS Ref. No. E05020150
AU04; pending IV. Canadian National Stage Patent Application No. 2979229 filed Mar. 11, 2016, HHS Ref. No. E05020150
CA05; pending V. European national Stage Patent Application No. 1662623.3 filed Oct. 11, 2016, HHS Ref. No. E05020150EP
06; issued validated in DE, FR and GB
VI. U.S. national Stage Patent Application No. 15/556,746 filed Sep. 8, 2017 HHS Ref. No. E05020150US
08; issued VII. Japanese National Stage Patent Application No. 2017547425 filed Sep.
8, 2017 HHS Ref. No. E05020150
JP07; pending VIII. Divisional European Patent Application No. 20176667.2 filed May 26, 2020 HHS Ref. No. E05020150
EP13; pending IX. Divisional Japanese Patent Application No. 2020167984 filed Oct.
2, 2020 HHS Ref. No. E05020150
JP14; pending The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America.
The prospective exclusive license territory may be worldwide, and the field of use may be limited to:
Development and commercialization of RP2 AAV-based gene human therapy for any ocular disease, disorder or condition, including human X-linked retinitis pigmentosa XLRP.
This technology discloses AdenoAssociated Viral AAV vectors comprising nucleotide sequences encoding RP2 or RPGRORF 15
transgenes and their use in treating or preventing X-linked forms of retinitis pigmentosa XLRP.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen 15 days from the date of this published notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public may file comments or objections.
Comments and objections, other than those in the form of a license
VerDate Sep<11>2014

17:26 Jul 09, 2021

Jkt 253001

application, will not be treated confidentially, and may be made publicly available.
License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information in these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C.
552.
Dated: July 2, 2021.
Richard U. Rodriguez, Associate Director, Technology Transfer Center, National Cancer Institute.
FR Doc. 202114682 Filed 7921; 8:45 am BILLING CODE 414001P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health Center for Scientific Review; Notice of Closed Meeting Pursuant to section 10d of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the provisions set forth in sections 552bc4 and 552bc6, Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Motor function in healthy and clinical populations.
Date: August 3, 2021.
Time: 1:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 Virtual Meeting.
Contact Person: Maribeth Champoux, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3170, MSC 7848, Bethesda, MD 20892, 301594
3163, champoum@csr.nih.gov.
Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333, 93.337, 93.39393.396, 93.83793.844, 93.84693.878, 93.892, 93.893, National Institutes of Health, HHS

PO 00000

Frm 00045

Fmt 4703

Sfmt 4703

Dated: July 6, 2021.
David W. Freeman, Program Analyst, Office of Federal Advisory Committee Policy.
FR Doc. 202114697 Filed 7921; 8:45 am BILLING CODE 414001P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health National Center for Complementary &
Integrative Health; Notice of Meeting Pursuant to section 10d of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Council for Complementary and Integrative Health.
The meeting will be closed to the public in accordance with the provisions set forth in sections 552bc4 and 552bc6, Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
The meeting will be held as a virtual meeting and is open to the public as indicated below. Individuals who plan to view the virtual meeting and need special assistance or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The Open Session will be open to the public via NIH Videocast.
The URL link to access this meeting is https videocast.nih.gov.
Name of Committee: National Advisory Council for Complementary and Integrative Health.
Date: September 10, 2021.
Closed: 10:00 a.m. to 11:30 a.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Democracy 2, 6707 Democracy Boulevard, Bethesda, MD 20817 Virtual Meeting.
Open: 11:40 a.m. to 5:00 p.m.
Agenda: A report from the Director of the Center and Other Staff.
Place: National Institutes of Health, Democracy 2, 6707 Democracy Boulevard, Bethesda, MD 20817 Virtual Meeting.
Contact Person: Partap Singh Khalsa, Ph.D., DC, Director, Division of Extramural Activities, National Center for Complementary and Integrative Health, National Institutes of Health, 6707
Democracy Blvd., Suite 401, Bethesda, MD
208925475, 3015943462, khalsap@
mail.nih.gov.
Any interested person may file written comments with the committee by forwarding
E:FRFM12JYN1.SGM

12JYN1